UK-based AI and machine learning firm PinPoint has raised more than £1 million to develop a test designed to rule out cancer in the early stages and save millions for the NHS in unnecessary testing.

Life Technologies acquired Pinpoint Genomics and its early-stage non-small-cell lung cancer test. The test is designed to identify early-stage patients at high risk for progression to late-stage ...

An inexpensive, fast accurate DNA test that reveals a person's risk of developing certain diseases is expected to become a reality, thanks to new technology. An inexpensive, fast, accurate DNA test ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. There's a new location game called Pinpoint on Windows Phone from the team behind Foundbite. As ...

CARLSBAD, Calif., July 25, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of Pinpoint Genomics, Inc., and its early-stage non-small cell lung cancer ...

Researchers are developing a blood test that can tell not only whether someone has cancer, but in what organ the tumors are lurking. The test could mean more prompt, potentially life-saving treatment ...

Colon cancer is one of the top three deadliest forms of cancer - in part because it's often diagnosed so late. Now a groundbreaking study could pinpoint the disease easier, and earlier. The ...

When a cell dies in a tumor, a growing fetus or elsewhere in the body, bits and pieces of its DNA enter the bloodstream. A new test that identifies the source of such DNA could make it easier to find ...